SCHEMBL2226451

SCHEMBL2226451

CCOC(=O)C(=CCC(C)C)CCC(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIK1 P39086 1/20 0.39
ALDH1A1 P00352 2/20 0.38
CYP2D6 P10635 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
EGLN1 Q9GZT9 1/20 0.36
KYAT1 Q16773 5/20 0.35
NPSR1 Q6W5P4 2/20 0.34
GLO1 Q04760 1/20 0.34
GABRP O00591 2/20 0.33
GABRD O14764 2/20 0.33
GABRA1 P14867 2/20 0.33
GABRB1 P18505 2/20 0.33
GABRG2 P18507 2/20 0.33
GABRB3 P28472 2/20 0.33
GABRA5 P31644 2/20 0.33
GABRA3 P34903 2/20 0.33
GABRA2 P47869 2/20 0.33
GABRB2 P47870 2/20 0.33
GABRA4 P48169 2/20 0.33
GABRE P78334 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28755858 0.83 GRIK1 (0.36) GRIK1ALDH1A1CYP2D6SMN1; SMN2NPSR1
SCHEMBL16152829 0.79 GRIK1 (0.41) GRIK1ALDH1A1CYP2D6SMN1; SMN2NPSR1
SCHEMBL3927257 0.78 GRIK1 (0.55) GRIK1CYP2D6EGLN1GABRPGABRD
SCHEMBL4661706 0.78 GAA (0.47) GRIK1ALDH1A1CYP2D6SMN1; SMN2EGLN1
SCHEMBL11398954 0.75 NPSR1 (0.42) ALDH1A1CYP2D6SMN1; SMN2EGLN1KYAT1
SCHEMBL1408810 0.74 NPSR1 (0.50) ALDH1A1CYP2D6SMN1; SMN2NPSR1GLO1
SCHEMBL5085513 0.74 NPSR1 (0.46) GRIK1ALDH1A1CYP2D6SMN1; SMN2EGLN1
SCHEMBL5085510 0.74 NPSR1 (0.46) GRIK1ALDH1A1CYP2D6SMN1; SMN2EGLN1
SCHEMBL28582961 0.73 CYP2D6 (0.45) GRIK1ALDH1A1CYP2D6SMN1; SMN2EGLN1
SCHEMBL12553979 0.72 NPSR1 (0.38) GRIK1ALDH1A1CYP2D6SMN1; SMN2EGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110256229-A A method of preparing 3- isobutylglutaric acid 常州工程职业技术学院 2019-09-20 CN claimed
CN-115536524-B Preparation method of 3-isobutyl glutaric acid 常州大学 2024-05-28 CN disclosed
CN-115536524-A Preparation method of 3-isobutyl glutaric acid 常州大学 2022-12-30 CN disclosed
CN-111333529-A Preparation method of pregabalin 北京万全德众医药生物技术有限公司 2020-06-26 CN disclosed
CN-110256229-A A method of preparing 3- isobutylglutaric acid 常州工程职业技术学院 2019-09-20 CN disclosed
WO-2011141923-A2 IMPROVED SYNTHESIS OF OPTICALLY PURE (S) - 3-CYANO-5-METHYL-HEXANOIC ACID ALKYL ESTER, AN INTERMEDIATE OF (S)- PREGABALIN LUPIN LIMITED (IN) 2011-11-17 WO disclosed
WO-2011086565-A1 METHOD FOR PREPARATION OF ENANTIOMERICALLY ENRICHED AND/OR RACEMIC GAMMA-AMINO ACIDS LUPIN LIMITED (IN) 2011-07-21 WO disclosed
WO-2010061403-A2 PROCESS TO PREPARE HIGHLY PURE (S)-PREGABALIN IND-SWIFT LABORATORIES LIMITED (IN) 2010-06-03 WO disclosed
WO-2009044409-A2 NOVEL RESOLUTION PROCESS FOR PREGABALIN NATCO PHARMA LIMITED (IN) 2009-04-09 WO disclosed
EP-0830338-B1 Method of making 3-(aminomethyl)-5-methylhexanoic acid WARNER LAMBERT CO (US) 2001-12-12 EP disclosed
US-20010016665-A1 METHOD OF MAKING (S)-3-(AMINOMETHYL) -5- METHYLHEXANOIC ACID GROTE TODD MICHEL (US) 2001-08-23 US disclosed
US-6046353-A Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid WARNER-LAMBERT COMPANY (US) 2000-04-04 US disclosed
US-5840956-A Method of making (S)-3-(Aminomethyl)-5-Methylhexanoic acid WARNER-LAMBERT COMPANY (US) 1998-11-24 US disclosed
EP-0830338-A1 METHOD OF MAKING (S)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID WARNER-LAMBERT COMPANY (US) 1998-03-25 EP disclosed
US-5637767-A Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid WARNER-LAMBERT COMPANY (US) 1997-06-10 US disclosed
WO-1996040617-A1 METHOD OF MAKING (S)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID WARNER-LAMBERT COMPANY (US) 1996-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010016665-A1 METHOD OF MAKING (S)-3-(AMINOMETHYL) -5- METHYLHEXANOIC ACID APEH, CA6, ALKBH3 GRIK1 964/4885ALDH1A1 316/4885CYP2D6 775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.